Accrued expenses increased by $16.8 million from December 31, 2025 to June 30, 2026, primarily driven by higher accrued compensation and accrued clinical trial costs. The increase in accrued compensation was primarily attributable to a $6.2 million increase in Director’s Deferred Share Unit-related accruals resulting from an increase in the Company's stock price in 2026 and a $5.7 million increase in accrued payroll taxes associated with settlements of RSUs expected to be made subsequent to June 30, 2026. The increase in accrued clinical trial costs was primarily attributable to increased expenses associated with the advancement of the Company's four Phase 3 clinical studies during the period.